MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

Home » Ocular Therapeutix closes $14 million D round | Funding roundup

Ocular Therapeutix closes $14 million D round | Funding roundup

By

Funding roundup

Here’s a roundup of the latest dealflow and investment news:

  • Ocular Therapeutix completes Series D financing to support Phase II sustained drug delivery clinical trials
    Ocular Therapeutix Inc. closed a $14 million Series D round of financing. The round was led by Ascension Health Ventures of St. Louis, Missouri, with continued participation by existing investors including Polaris Ventures, SV Life Sciences and Versant Ventures. The funding will be used to support Ocular Therapeutix’s Phase II clinical trials across a variety of therapeutic areas. The first trial will be conducted to reinforce safety and test efficacy of their first sustained drug delivery system, a moxifloxacin-loaded punctum plug. Following, Ocular Therapeutix plans to initiate additional Phase II clinical trials for punctum plugs designed for the management of glaucoma, dry eye, and allergies.
    Read more

  • Massive Health drums up $2.25 million
    San Francisco-based Massive Health announced a $2.25 million round with Mohr Davidow, Andreessen Horowitz, Charles River Ventures, Felicis VC, the Collaborative Fund and Greylock Partners, according to PE Hub. Several angels also are in the deal. The company is designing a mobile app to manage disease by using social graphs and social networks and help people stay well.
    Read more

  • Seattle Genetics announces exercise of over-allotment option
    Seattle Genetics Inc. (NSDQ:SGEN) announced that the underwriters of its previously announced public offering of common stock have exercised in full their option to purchase an additional 1,500,000 shares of common stock. Gross proceeds from the offering of an aggregate of 11,500,000 shares at a price to the public of $15.50 per share, before underwriting discounts and commissions and other offering expenses, will be approximately $178 million. The offering is expected to close on February 7, 2011, subject to customary closing conditions.
    Read more

  • VertiFlex announces financing and new investment partner
    VertiFlex Inc., a percutaneous and motion preserving spinal surgery technologies company, completed of a $14 million equity placement, with provision for an additional $14 million investment within twelve months. Current investors Aberdare Ventures, Alta Partners and New Enterprise Associates were joined in the financing by new investor Thomas, McNerney & Partners. The new capital will be used to complete enrollment in the Superion Interspinous Spacer (ISS) IDE Trial before the end of 2011, and to advance global market development of the technology.
    Read more

  • Spine Wave drums up $17.5 million
    Shelton, Conn.-based Spine Wave Inc. raised $17.5 million in a funding round led by former investor New Enterprise Associates. Morgenthaler Ventures, Compass Global Fund, New Leaf Venture Partners, Canaan Partners, Foundation Medical Partners and Memphis Implant Partners also backed the round. The company plans use the funding to grow its commercial operations and help bring its NuCore Injectable Nucleus to clinical trials.
    Read more

In case you missed it

RSS From Medical Design & Outsourcing

  • First OTC molecular test for COVID-19 gains FDA nod
    The FDA today issued its first emergency use authorization for a molecular COVID-19 diagnostic test for at-home use without a prescription. The Cue Health COVID-19 Test for Home and Over The Counter (OTC) use is a molecular nucleic acid amplification test designed to detect genetic material from the SARS-CoV-2 virus in the nostrils. The authorized… […]
  • A wearable jaundice monitor for newborns?
    Researchers in Japan say they have developed the first wearable device to precisely monitor jaundice, a yellowing of the skin caused by elevated bilirubin levels in the blood that can cause severe medical conditions — even death — in newborns. Jaundice can be treated easily by irradiating the infant with blue light that breaks bilirubin… […]
  • Plastikos to double size of medical manufacturing operation
    Plastikos announced today that the second phase of construction on its Plastikos Medical plant will begin this month. The Erie, Pa.-based company completed the first building in its medical business in 2019 and has added 10 medical injection molding machines since then. The second building will more than double the size of the current ISO-7 cleanroom… […]
  • Paxxus sealant updated for EU-MDR
    Paxxus announced this week that its Chameleon color-changing package seal indicator technology now works with uncoated Tyvek used to package medical devices. Addison, Ill.-based Paxxus said it updated the technology in advance of a new packaging regulation set to go into effect in the EU in May. Chameleon now shows a vivid color-seal indicator when… […]
  • Medtronic hiring Walmart exec to run its supply chain
    Medtronic (NYSE:MDT) CEO Geoff Martha announced that the company is appointing Greg Smith as EVP of global operations and supply chain. In a LinkedIn post today, Martha wrote: “I’m pleased to share that Greg Smith, Executive Vice President of U.S. Supply Chain for Walmart, is joining Medtronic on April 5 as Executive Vice President of… […]
  • Philips and Disney want to make MRIs easier for children: Here’s how
    Royal Philips (NYSE:PHG) announced today that it is teaming up with Disney to test the effects of custom-made animation to create a relaxing atmosphere for young patients. Amsterdam-based Philips will collaborate with The Walt Disney Company EMEA to see whether the animation, including specially-made Disney stories within Philips’ Ambient Experience, creates a relaxing atmosphere to improve… […]
  • Origami Surgical gains FDA clearance for robotic suturing devices
    Origami Surgical today announced that the FDA has granted 510(k) clearance for three new types of sutures for its StitchKit robotic surgery platform. The company describes StitchKit as a patented suture delivery and retrieval system designed so sutures are efficiently inserted and needles are safely removed from the surgical field. StitchKit also allows the robotic… […]
  • NAMSA acquires American Preclinical Services
    Contract research organization NAMSA today announced its acquisition of Minneapolis-based American Preclinical Services (APS). This purchase follows NAMSA’s acquisition of New York-based Syntactx, a clinical research services CRO, in January. The acquisition will provide NAMSA customers with a broader range of laboratory models and analysis tools, including innovative surgical instrumentation and several state-of-the-art catheterization labs,… […]
  • 5 reasons Medtronic’s CEO is optimistic about the future
    Nearly a year after Geoff Martha took over the corner office at Medtronic, the world’s largest medical device company is transforming. In a recent interview with our DeviceTalks Weekly podcast, Martha detailed Medtronic‘s major reorganization, its shift in corporate culture and more. Martha was also highly pleased about Medtronic’s recent Q3 earnings results. Here are… […]
  • Medtronic is changing a lot: Here’s what you need to know
    CEO Geoff Martha says Medtronic‘s ongoing corporate restructuring will position the company to compete better with medical device rivals, freeing the front-line forces from earlier entanglements. But the change will also create new opportunities for Medtronic employees at the company and elsewhere. In a far-ranging interview with the DeviceTalks Weekly podcast, Martha reviewed the company’s… […]
  • Pharma’s been slow to adopt Industry 4.0 — but that could change
    The pharma industry has been relatively slow to embrace concepts such as Industry 4.0, but COVID-19 is serving as a catalyst for sweeping changes within the industry. The philosophy has roots in a German framework that prioritizes digitization to drive manufacturing efficiency, promising that cyber-physical systems will usher in the next industrial revolution. The Industry… […]

Leave a Reply